Philogen Logo

Philogen

PHIL | XMIL

Overview

Corporate Details

ISIN(s):
IT0005373789 (+1 more)
LEI:
81560009EA1577917768
Country:
Italy
Address:
PIAZZA LA LIZZA, 7, 53100 SIENA
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Philogen is a fully-integrated, clinical-stage biotechnology company founded in 1996. It specializes in the discovery and development of innovative biopharmaceuticals for the targeted treatment of cancer, chronic inflammatory diseases, and other serious conditions associated with angiogenesis. The company's proprietary technology platform enables the creation of novel antibody-based therapeutics, such as immunocytokines, designed to selectively deliver therapeutic agents to the site of disease. Philogen's capabilities span from research and discovery through to GMP manufacturing and clinical development of its pipeline products.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Philogen. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-18 20:02
M&A Activity
Press Release Clearance e Closing OncoACP3 (Price Sensitive)
Italian 213.9 KB
2025-07-07 16:50
Transaction in Own Shares
2025 07 07 - CS settimanale acquisto azioni proprie
Italian 153.0 KB
2025-07-07 12:08
Regulatory News Service
Allegato 3F
Italian 26.7 KB
2025-06-30 17:04
Transaction in Own Shares
2025 06 30 - CS settimanale acquisto azioni proprie
Italian 181.7 KB
2025-06-25 12:29
Legal Proceedings Report
Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in…
English 180.5 KB
2025-06-11 01:34
Regulatory News Service
Press Release Licenza OncoACP3 (Price Sensitive)
Italian 225.0 KB
2025-06-03 13:40
Transaction in Own Shares
2025 06 03 - CS settimanale acquisto azioni proprie
Italian 144.1 KB
2025-05-26 17:46
Registration Form
Statuto
Italian 261.6 KB
2025-05-26 17:24
Post-Annual General Meeting Information
Deposito del Verbale dell'Assemblea degli Azionisti
Italian 131.0 KB
2025-05-26 17:22
Pre-Annual General Meeting Information
Verbale dei lavori dell'Assemblea Ordinaria e Straordinaria degli Azionisti
Italian 30.4 MB
2025-05-26 15:09
Transaction in Own Shares
2025 05 26 - CS settimanale acquisto azioni proprie
Italian 147.5 KB
2025-05-19 12:24
Transaction in Own Shares
2025 05 19 - CS settimanale acquisto azioni proprie
Italian 130.7 KB
2025-05-12 15:04
Transaction in Own Shares
2025 05 12 - CS settimanale acquisto azioni proprie
Italian 141.2 KB
2025-05-07 10:30
Director's Dealing
Allegato 3F
Italian 27.5 KB
2025-05-06 18:56
Post-Annual General Meeting Information
Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa…
Italian 259.8 KB

Automate Your Workflow. Get a real-time feed of all Philogen filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Philogen via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A